3 Material Selection Mistakes That Derail Biocompatibility—Joyworks Problem-Solving Guide

Biocompatibility testing is a gatekeeper in medical device development, yet many teams stumble early by making preventable material selection errors. This guide, prepared by the editorial team at Joyworks, examines three common mistakes—overlooking processing effects, neglecting extractables and leachables (E&L) testing, and ignoring surface interactions—and offers a structured problem-solving framework to address them. Drawing on industry patterns and anonymized examples, we aim to help you avoid costly rework and regulatory setbacks. As of May 2026, the principles described reflect widely shared practices; always verify details against current official guidance.

Mistake 1: Overlooking How Processing Alters Material Biocompatibility

One of the most common pitfalls in material selection is assuming that a raw material's biocompatibility remains unchanged after manufacturing processes. Many teams select a polymer or metal based on its established biocompatibility profile from a supplier datasheet, only to discover later that molding, extrusion, sterilization, or surface treatments have introduced new chemical species or altered surface properties. For instance, a thermoplastic polyurethane that passes ISO 10993 tests as a resin may show cytotoxicity after injection molding due to residual mold release agents or thermal degradation byproducts. Similarly, gamma sterilization of polycarbonate can generate radiolytic species that leach into surrounding tissues, triggering inflammatory responses. The root cause is a mismatch between the tested condition (raw material) and the final device condition (processed material).

Why This Happens: The Chemistry of Change

Processing introduces heat, shear, radiation, or chemical exposure that can break polymer chains, create free radicals, or form new low-molecular-weight compounds. These byproducts may be cytotoxic, mutagenic, or immunogenic. For example, during injection molding of polyether ether ketone (PEEK), temperatures above 400°C can cause slight degradation, yielding oligomers not present in the virgin pellet. While such changes are often within acceptable limits for mechanical properties, they can shift biocompatibility endpoints. A team developing a spinal cage once used medical-grade PEEK but observed unexpected cytotoxicity in the molded part. Investigation revealed that the molder had not purged the barrel between runs, introducing trace polyethylene contamination that caused the failure.

The Cost of Neglect

Discovering a process-induced biocompatibility issue late in development—during formal ISO 10993 testing—can add months and hundreds of thousands of dollars to a project. The device may require a material change, process revalidation, and new biocompatibility studies. In one composite scenario, a catheter manufacturer faced a six-month delay because a plasticizer migrated from a PVC hub during ethylene oxide sterilization, requiring reformulation and retesting. The financial and timeline impact underscores the need for early assessment.

How to Prevent This Mistake

Adopt a 'process–material iteration' approach: select candidate materials and then subject them to the intended manufacturing steps before sending samples for biocompatibility screening. Use small-scale process simulations to produce test coupons that represent the worst-case processing conditions (e.g., highest temperature, longest residence time). Conduct early cytotoxicity and chemical characterization on these processed samples—not on raw material specimens. Maintain a material–process history log that documents every thermal, mechanical, and chemical exposure. When outsourcing manufacturing, require your supplier to provide documentation of processing parameters and to run qualification batches that mimic your production cycle. By building process representativeness into your biocompatibility strategy, you catch problems before full-scale testing.

Mistake 2: Neglecting Extractables and Leachables Screening in Early Material Selection

Extractables and leachables (E&L) testing is often perceived as a late-stage regulatory hurdle, but delaying it until after material selection is a strategic error. E&L studies identify compounds that can migrate from a device into the patient or drug product, and they are critical for devices with prolonged patient contact or combination products. Many teams choose materials based solely on mechanical properties and published biocompatibility data, only to discover that the device leaches unacceptable levels of a plasticizer, antioxidant, or processing aid. For example, a drug-eluting stent manufacturer selected a polyurethane that had general biocompatibility clearance, but during E&L analysis under simulated use conditions, high levels of a phenolic antioxidant leached out, potentially interfering with the drug coating and raising toxicological concerns. The team had to reformulate, causing a year-long delay.

The Science Behind E&L

Extractables are compounds that can be forced out of a material under aggressive solvent conditions (e.g., isopropanol, hexane, or simulated body fluids at elevated temperature). Leachables are the subset that actually migrate into the patient under clinical use. International standards such as ISO 10993-18 and USP guide the chemical characterization process. The key is to perform a controlled extraction study early, using the final device geometry and intended contact conditions, to profile the chemical 'fingerprint' of each candidate material. This fingerprint includes additives, monomers, oligomers, and degradation products. By comparing these profiles against toxicological thresholds, you can eliminate materials that pose inherent leaching risks before committing to full device design.

A Practical Early Screening Workflow

Integrate E&L screening into your material selection process: (1) For each candidate material, obtain a certificate of analysis from the supplier listing all additives, residual monomers, and processing aids. (2) Perform a worst-case extraction using a polar and a non-polar solvent (e.g., water and ethanol) at 50°C for 72 hours. (3) Analyze extracts using GC-MS and LC-MS to identify and semi-quantify organic compounds. (4) Compare results to toxicological thresholds from sources like the ICH Q3D or ECHA. (5) Eliminate materials with extractables above 10% of the toxicological concern level. This upfront investment—typically a few thousand dollars per material—can prevent months of rework. One team developing a wearable insulin pump used this workflow and identified that a silicone adhesive leached a cyclic siloxane above safe limits, prompting a switch to a different adhesive early in design.

When to Use More Rigorous Testing

For devices with long-term (>30 days) or permanent contact, or for combination products, early E&L screening should be followed by a full extractables study per ISO 10993-18. For short-term devices, a targeted screen may suffice. The goal is to match the depth of testing to the risk profile. By embedding E&L thinking early, you avoid the shock of discovering a leaching problem during regulatory submission, when options are limited and costly.

Mistake 3: Ignoring Surface Interactions and Their Biological Consequences

Material selection often focuses on bulk properties—strength, flexibility, durability—while surface characteristics receive less attention until later stages. However, the surface is the interface between device and biology, and its chemistry, topography, and energy dictate protein adsorption, cell adhesion, and immune response. A material that is biocompatible in bulk may trigger a foreign body reaction because its surface is hydrophobic, rough, or chemically active. For instance, a team developing a neural electrode selected a platinum–iridium alloy known for conductivity and corrosion resistance. However, the as-machined surface had microscale roughness and residual oxides that caused chronic inflammation and gliosis, degrading signal quality over time. A simple electropolishing step to reduce roughness and remove oxide layers dramatically improved long-term performance.

Key Surface Properties That Matter

Four surface parameters significantly influence biocompatibility: (1) Wettability (contact angle)—hydrophilic surfaces tend to reduce non-specific protein adsorption and promote cell adhesion, while hydrophobic surfaces often trigger denaturation and immune recognition. (2) Topography—micrometer and nanometer features can direct cell behavior; for example, surfaces with aligned grooves guide neurite outgrowth, while random roughness may promote fibrosis. (3) Chemistry—functional groups like hydroxyl, carboxyl, or amine can be intentionally introduced to modulate biointeractions. (4) Charge—zeta potential affects protein binding and bacterial adhesion. Each of these can be altered by processing, sterilization, or storage. A common oversight is assuming that a polished surface in the datasheet remains unchanged after ethylene oxide sterilization, which can deposit residues that shift surface energy.

Case Scenario: Surface Modification as a Solution

A developer of vascular grafts selected expanded polytetrafluoroethylene (ePTFE) for its mechanical properties and established use. However, early animal studies showed poor endothelialization and high thrombogenicity. Investigation revealed that the ePTFE surface was highly hydrophobic and had microporous structure that trapped air bubbles, preventing cell attachment. The team applied a plasma treatment to introduce hydrophilic functional groups, which improved endothelial cell coverage from 15% to 70% in vitro. This surface modification was performed before sterilization, and the graft passed subsequent ISO 10993 testing with no new leachables. The lesson: surface properties are not fixed; they can be engineered to meet biological requirements, but only if you account for them from the start.

Strategies to Avoid Surface-Related Failures

During material selection, characterize surface properties of candidate materials in the final processed form. Use contact angle goniometry, profilometry (or AFM for nanoscale), and XPS for chemistry. If a candidate has favorable bulk properties but poor surface characteristics, evaluate surface modification options—plasma, chemical grafting, or coating—and test their effect on biocompatibility early. Maintain a surface properties matrix that tracks how each process step alters the surface. By integrating surface science into material selection, you avoid the classic trap of a bulk-compatible material failing at the interface.

A Step-by-Step Material Selection Workflow to Prevent These Mistakes

To systematically avoid the three mistakes described, implement a structured material selection workflow that integrates process representativeness, early E&L screening, and surface characterization. This workflow is designed for medical device teams at any stage, but is most impactful when applied during concept and feasibility phases. Below is a repeatable process with five gates, each with specific deliverables.

Gate 1: Define Requirements and Constraints

Begin by listing all functional, regulatory, and manufacturing requirements. Include mechanical properties (tensile modulus, elongation, fatigue life), chemical resistance (to sterilization, drugs, body fluids), biocompatibility endpoints (cytotoxicity, sensitization, irritation, systemic toxicity), and regulatory pathway (e.g., 510(k) vs. PMA). Also note contact duration (limited, prolonged, permanent) and tissue type (bone, blood, soft tissue). This list becomes the filter for candidate materials. For example, a device contacting blood for less than 24 hours requires different hemocompatibility data than an implant expected to last 10 years.

Gate 2: Generate Candidate Materials List

From the requirements, compile 5–10 candidate materials from three categories: metals/alloys (e.g., stainless steel, titanium, nitinol), polymers (e.g., PEEK, polycarbonate, silicone), and ceramics (e.g., alumina, zirconia). Use supplier datasheets, published biocompatibility summaries, and previous project experience. For each candidate, note known biocompatibility data, processing methods, and available surface modifications. Avoid selecting materials based only on one property—for instance, choosing a polymer solely for lubricity without checking its E&L profile.

Gate 3: Perform Process-Representative Biocompatibility Screening

For each candidate, create test coupons that undergo the intended manufacturing steps (molding, extrusion, sterilization, etc.) at worst-case settings. Send these coupons for cytotoxicity testing per ISO 10993-5 (MEM elution or direct contact) and chemical characterization per ISO 10993-18. This gate eliminates materials that fail due to processing-induced toxicity. In one anonymized example, a team screening three polycarbonates found that one passed as raw but failed after gamma sterilization, while another passed both—saving them from a late-stage failure.

Gate 4: Conduct Early E&L and Surface Analysis

On the surviving candidates, perform a targeted extractables screen using two solvents and GC-MS/LC-MS. Also measure surface contact angle, roughness, and chemistry. Compare extractable profiles to toxicological thresholds. If a material shows high extractables or unfavorable surface properties (e.g., contact angle >90° for a blood-contacting device), either eliminate it or plan for surface modification. Document all data in a material selection matrix. This gate typically reduces the candidate list to 2–3 materials.

Gate 5: Downselect and Validate

Select the top candidate(s) based on all data, including cost and supply chain considerations. Then conduct a full biocompatibility test plan (ISO 10993 series) on the final device with the chosen material and process. Use the earlier screening results to anticipate and mitigate any remaining risks. This workflow, while requiring upfront investment, reduces the probability of expensive late-stage failures and accelerates time to market. Teams that follow it consistently report fewer 'surprises' during regulatory review.

Tools, Testing Economics, and Maintenance Realities

Implementing the workflow above requires access to tools and a realistic understanding of costs. This section reviews common testing options, their approximate economics, and the ongoing maintenance of biocompatibility documentation.

Testing Options and Cost Comparison

Several types of testing services are available, ranging from basic cytotoxicity kits to comprehensive E&L analysis. The table below compares three common approaches: in-house screening, contract lab basic panels, and contract lab full characterization.

In-house screening offers speed and low cost but limited scope. Contract labs provide regulatory-grade data but require careful selection—look for labs with ISO 17025 accreditation and experience with your device type. Many teams start with in-house cytotoxicity to filter materials, then send the top 2–3 to a contract lab for E&L and surface analysis. This hybrid approach balances cost and rigor.

Maintenance of Biocompatibility Documentation

Biocompatibility is not a one-time assessment. Changes in material supplier, processing parameters, sterilization cycle, or device design can all affect biocompatibility. Maintain a 'biocompatibility master file' that includes: (1) a material–process history for each component, (2) all biocompatibility test reports with dates, (3) a risk assessment for any changes, and (4) a change control procedure that triggers re-evaluation. For example, if a supplier changes the additive package in a polymer, you may need to repeat E&L testing. Regularly review your file at least annually or whenever a change occurs. This practice not only supports regulatory compliance but also builds institutional knowledge that speeds future projects.

Growth Mechanics: Building Organizational Competence in Biocompatibility

Beyond individual projects, organizations that excel at biocompatibility material selection develop systematic capabilities that compound over time. This section explores how teams can build knowledge, improve decision-making, and leverage early successes for regulatory and business advantage.

Create a Material Knowledge Repository

Every biocompatibility test, failure, and success contains data that can inform future selections. Establish a centralized database (e.g., a spreadsheet or a dedicated software tool) that records for each material: supplier, lot number, processing parameters, sterilization method, biocompatibility test results, and key lessons. Over several projects, this repository becomes a proprietary reference that reduces the need for repeated screening. For instance, one team documented that a particular polyurethane batch from a specific supplier consistently passed all tests after ethylene oxide sterilization, while another supplier's batch of the same grade failed due to a different antioxidant package. Without the repository, that knowledge would have been lost when the team members moved on.

Foster Cross-Functional Collaboration

Biocompatibility is not solely the domain of a regulatory specialist. Material selection decisions involve design engineers, process engineers, quality, and supply chain. Hold cross-functional reviews at each gate of the workflow. The design engineer may prioritize stiffness, but the process engineer can flag that the high stiffness material requires processing temperatures that degrade a key additive. The supply chain team can identify if a material has long lead times or is sourced from a single supplier, introducing risk. By involving all functions early, you avoid decisions that optimize one parameter at the expense of biocompatibility. In practice, teams that hold monthly 'biocompatibility roundtables' report fewer late-stage surprises.

Leverage Early Successes for Regulatory Strategy

A well-documented material selection process can streamline regulatory submissions. When a device reaches a notified body or FDA reviewer, the submission can include a summary of the material selection workflow, the screening data, and the rationale for the chosen material. This demonstrates a systematic, risk-based approach—a hallmark of quality system maturity. Some teams use the screening data to justify reduced animal testing (e.g., waiving sensitization studies if the material shows no extractables of concern). While regulators make the final decision, a robust data package can support such requests. Over time, a track record of successful submissions builds credibility with reviewers, potentially reducing review times for future devices.

Continuous Improvement Through Post-Market Surveillance

Biocompatibility knowledge does not end at market approval. Post-market surveillance (e.g., complaint monitoring, literature reviews) can reveal unexpected biological responses that trace back to material choices. Incorporate those findings into your material repository and update your selection criteria. For example, if a device experiences late inflammatory reactions, investigate whether a change in supplier or process occurred. Feed that insight back into the early screening phase of new projects. This closed-loop learning transforms biocompatibility from a compliance hurdle into a competitive advantage, as your organization becomes more adept at selecting materials that perform well in the real world.

Risks, Pitfalls, and Mitigations: A Deeper Look at Failure Modes

Even with a robust workflow, teams can encounter pitfalls. This section identifies common failure modes and offers specific mitigations, drawing from anonymized industry experiences.

Pitfall 1: Relying on Supplier Data Without Verification

Supplier biocompatibility data is often generated on a different form (e.g., film vs. molded part) or under different processing conditions. A supplier may test a polymer with a specific additive package that later changes without notice. Mitigation: Always verify critical biocompatibility endpoints on your specific processed material. Request the supplier's complete test reports and compare their test conditions to yours. Establish a supplier change notification agreement that requires them to inform you of any formulation or process changes at least 90 days in advance. This gives you time to assess impact before production.

Pitfall 2: Underestimating the Effect of Sterilization

Sterilization is a process step that can dramatically alter material biocompatibility. Ethylene oxide (EO) sterilization can leave residual EO and its byproducts (ethylene chlorohydrin, ethylene glycol) on the surface, which are toxic. Gamma sterilization can cause crosslinking or chain scission, altering extractables. Steam sterilization can hydrolyze polymers. Mitigation: Sterilize your test coupons using the same method and cycle parameters as the production device. Include sterility testing and biocompatibility testing on the sterilized parts. If multiple sterilization methods are possible, test the worst-case (e.g., the one that produces the most extractables). Document the sterilization validation plan early.

Pitfall 3: Ignoring the Biological Endpoint of the Device

Different biological endpoints require different material properties. A material that is excellent for a bone implant (good osseointegration, low inflammation) may be poor for a blood-contacting device (high thrombogenicity). Mitigation: Align material selection with the specific biological environment. For blood-contacting devices, prioritize hemocompatibility (hemolysis, thrombosis, complement activation). For neural devices, prioritize cytotoxicity and inflammatory response. Use the ISO 10993-1 matrix to identify which endpoints apply to your device category, and select materials that have favorable data for those endpoints. If data is lacking, plan for targeted testing.

Pitfall 4: Failing to Plan for Raw Material Variability

Even within a single grade from a single supplier, batch-to-batch variability can affect biocompatibility. A change in the manufacturing process of the raw material—such as a new catalyst or different drying conditions—can introduce new extractables. Mitigation: For critical materials, establish incoming quality control tests that include a simple cytotoxicity screen or FTIR fingerprinting to detect significant changes. Work with suppliers to understand their process control and request that they hold a reference sample of the material used for your original biocompatibility tests. If a batch fails, you can compare it to the reference to identify the cause.

Pitfall 5: Overlooking the Impact of Storage and Aging

Materials can degrade over time, especially if stored in unfavorable conditions (heat, humidity, UV light). Degradation can produce new extractables or change surface properties. Mitigation: Include accelerated aging (e.g., 55°C, 80% humidity for 4 weeks) as part of your material screening. Test the aged material for cytotoxicity and extractables. This is especially important for devices with long shelf lives. Document the shelf life rationale in your submission.

Mini-FAQ: Common Questions About Material Selection for Biocompatibility

This section addresses frequent concerns voiced by medical device teams. The answers are based on general industry practices and should be verified against your specific regulatory context.

Q1: Can we use a material that has a published ISO 10993 certificate from the supplier without doing our own testing?

Generally, no. Supplier certificates are valuable but often cover the material in a standard form (e.g., resin pellets) and under unspecified processing conditions. Your processed device may have different surface chemistry, extractables, or mechanical stress. Regulatory bodies expect that you demonstrate biocompatibility on the final device or on representative samples processed identically. However, you may be able to leverage supplier data as part of a weight-of-evidence approach if you can show equivalence in processing and geometry. Always consult with your regulatory team before relying solely on supplier data.

Q2: When should we start E&L testing?

Start E&L screening as early as material selection, using a targeted approach on processed coupons. Full E&L studies (per ISO 10993-18) are typically performed on the final device design, but early screening helps eliminate bad candidates. For combination products, E&L testing should be integrated into drug–device interaction studies from the beginning.

Q3: Is surface modification a viable way to 'fix' a material that has poor biocompatibility?

Yes, but it must be validated. Surface modification (plasma, coating, chemical grafting) can improve wettability, reduce protein adsorption, or promote cell adhesion. However, the modification must be stable through sterilization and storage, and it must not introduce new toxicological concerns. Include surface-modified samples in your biocompatibility test plan. Also consider that surface modifications can add cost and complexity to manufacturing.

Q4: How do we handle multiple contact durations or tissue types in one device?

Each component of the device may have different contact duration and tissue type. For example, a catheter may have a short-term external portion and a long-term intravascular segment. Perform biocompatibility testing on each distinct material–tissue interface, or on a worst-case combination. Document the rationale for your testing strategy in the risk management file.

Q5: What is the most common regulatory finding related to material selection?

One frequent finding is incomplete justification for material selection, especially when the material differs from predicates. Reviewers expect a clear rationale linking material properties to device function and biological safety. Another common finding is insufficient characterization of processing effects. By following the workflow in this guide, you can address both expectations proactively.

Synthesis and Next Actions

Material selection for biocompatibility is a multidimensional challenge that requires integrating material science, process engineering, and regulatory knowledge. The three mistakes highlighted—ignoring processing effects, neglecting early E&L screening, and overlooking surface interactions—are interconnected; each can derail a project independently, but together they represent a systemic failure to consider the full lifecycle of the material in the device. By adopting a structured workflow that includes process-representative screening, early E&L analysis, and surface characterization, teams can catch problems early and avoid costly late-stage changes.

Start with a cross-functional review of your current material selection process. Identify which of the three mistakes are most relevant to your device type and development stage. For example, if you are developing an implantable device with long-term contact, prioritize E&L and surface characterization. If you are using a new polymer grade, focus on processing effects. Implement the five-gate workflow incrementally—you do not need to overhaul everything at once. Even adding a single gate, such as creating process-representative coupons for cytotoxicity screening, can significantly reduce risk.

Document your process and results in a material selection matrix that includes all data from screening. This matrix becomes a living record that supports regulatory submissions and informs future projects. Share lessons learned across your organization to build institutional competence. Finally, recognize that biocompatibility is not a static property but a dynamic interaction among material, process, and biology. Stay current with evolving standards and regulatory expectations by attending industry conferences, participating in standards committees, or following guidance from the FDA and ISO. By treating material selection as a systematic, evidence-based process, you not only avoid common mistakes but also accelerate your path to a safe, effective, and compliant medical device.